Pyruvate Kinase Thermostability Is Associated with Red Blood Cell Adhesion, Deformability and Oxygen Affinity in Patients with Sickle Cell Disease

Introduction: Sickle cell disease(SCD) is caused by a mutation in the beta globin gene that causes formation of abnormal hemoglobin S (HbS). Red blood cells (RBCs) from patients with SCD are less deformable and take on the shape of sickle upon deoxygenation. This results in multiple downstream effec...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Blood 2023-11, Vol.142 (Supplement 1), p.561-561
Hauptverfasser: Traets, Marissa J.M., van der Veen, Sigrid, Bos, Jennifer, van Pelt, Laura, Kidane, Aida, van Oirschot, Brigitte A., van Solinge, Wouter W., Schols, Saskia, Lauw, Mandy N., Cnossen, Marjon H., Nur, Erfan, Biemond, Bart J., Van Beers, Eduard J., Rijneveld, Anita W., van Wijk, Richard, Rab, Minke A.E.
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 561
container_issue Supplement 1
container_start_page 561
container_title Blood
container_volume 142
creator Traets, Marissa J.M.
van der Veen, Sigrid
Bos, Jennifer
van Pelt, Laura
Kidane, Aida
van Oirschot, Brigitte A.
van Solinge, Wouter W.
Schols, Saskia
Lauw, Mandy N.
Cnossen, Marjon H.
Nur, Erfan
Biemond, Bart J.
Van Beers, Eduard J.
Rijneveld, Anita W.
van Wijk, Richard
Rab, Minke A.E.
description Introduction: Sickle cell disease(SCD) is caused by a mutation in the beta globin gene that causes formation of abnormal hemoglobin S (HbS). Red blood cells (RBCs) from patients with SCD are less deformable and take on the shape of sickle upon deoxygenation. This results in multiple downstream effects including RBC adhesion, microvascular occlusion and chronic hemolysis. RBCs rely solely on anaerobic glycolysis to produce adenosine triphosphate (ATP), which is needed to maintain the cell's structure and function. Pyruvate kinase (PK) is a key enzyme involved in the last step of glycolysis. We have previously demonstrated a decrease in PK activity and stability as a novel pathophysiological feature of SCD. Currently there are several clinical trials ongoing investigating the efficacy of PK activation by small molecules such as mitapivat (NL8517, NCT04000165, NCT05031780), AG-946 (NCT04536792) and etavopivat (NCT04624659, NCT04987489). In this study we aim to investigate how PK properties correlate to sickle RBC properties in order to explore if impaired PK function is associated with specific features of the complex SCD pathophysiology. Methods: Homozygous HbS (HbSS) and HbS/ β 0 thalassemia patients were eligible to participate. Patients who received blood transfusion (41 g/dL, Advia 120/2120 Siemens) and HbF and HbS levels (Tosoh G8) were measured. PK and hexokinase (HK) activity were measured on purified RBCs. PK thermostability (reflected by % residual PK activity) was measured on purified RBCs lysates after one hour of incubation (53°C). RBC adhesion to laminin (Biolamina) was measured using a microfluidic device (IBIDI µ-Slide I 0.4). RBC hydration (Ohyper), RBC deformability (EImax) and point of sickling (PoS) were assessed by osmotic and oxygen gradient ektacytometry using the Laser-Optical Rotational Red Cell Analyzer (Lorrca, RR Mechatronics). Oxygen affinity (P50) was measured with the Hemox-Analyzer (TCS). Statistical analysis was performed in Graphpad Prism (Pearson's correlation). Results: Fifty-seven patients with SCD (53 HbSS, 4 HbS/β 0 thalassemia) were included of which 17 were children (median age 14 years [range 6-17]) and 40 were adults (median age 36 years [range 18-58]). Baseline characteristics are depicted in Table 1. Figure 1 shows a heatmap with correlation coefficients of all laboratory parameters from Table 1 as measured in this cohort. When focusing on PK properties we found that pati
doi_str_mv 10.1182/blood-2023-180755
format Article
fullrecord <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1182_blood_2023_180755</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0006497123051650</els_id><sourcerecordid>S0006497123051650</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1375-a38478a487ea3cb6b50743dd6b0ecd4f64d876e502ab62d15d77b191d7e4fc7d3</originalsourceid><addsrcrecordid>eNp9kE1OwzAQhS0EEqVwAHY-AAE7seNUrELLT0WlVlDWlmNPqCGNkR0KuQYnJiGwZTWj0bw3bz6ETik5pzSLL4rKORPFJE4imhHB-R4aUR5nESEx2UcjQkgasYmgh-gohBdCKEtiPkJfq9a_71QD-N7WKgBeb8BvXWhUYSvbtHgecB6C07bbMfjDNhv80DVX_T08harCudlAsK4-wzMond_-KVVt8PKzfYYa52Vp635ma7xSjYW6CYPXo9WvFQxGMxugi3CMDkpVBTj5rWP0dHO9nt5Fi-XtfJovIk0TwSOVZExkimUCVKKLtOBEsMSYtCCgDStTZjKRAiexKtLYUG6EKOiEGgGs1MIkY0QHX-1dCB5K-ebtVvlWUiJ7qPIHquyhygFqp7kcNNAF21nwMujuGw3GetCNNM7-o_4GObuCAQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Pyruvate Kinase Thermostability Is Associated with Red Blood Cell Adhesion, Deformability and Oxygen Affinity in Patients with Sickle Cell Disease</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Traets, Marissa J.M. ; van der Veen, Sigrid ; Bos, Jennifer ; van Pelt, Laura ; Kidane, Aida ; van Oirschot, Brigitte A. ; van Solinge, Wouter W. ; Schols, Saskia ; Lauw, Mandy N. ; Cnossen, Marjon H. ; Nur, Erfan ; Biemond, Bart J. ; Van Beers, Eduard J. ; Rijneveld, Anita W. ; van Wijk, Richard ; Rab, Minke A.E.</creator><creatorcontrib>Traets, Marissa J.M. ; van der Veen, Sigrid ; Bos, Jennifer ; van Pelt, Laura ; Kidane, Aida ; van Oirschot, Brigitte A. ; van Solinge, Wouter W. ; Schols, Saskia ; Lauw, Mandy N. ; Cnossen, Marjon H. ; Nur, Erfan ; Biemond, Bart J. ; Van Beers, Eduard J. ; Rijneveld, Anita W. ; van Wijk, Richard ; Rab, Minke A.E.</creatorcontrib><description>Introduction: Sickle cell disease(SCD) is caused by a mutation in the beta globin gene that causes formation of abnormal hemoglobin S (HbS). Red blood cells (RBCs) from patients with SCD are less deformable and take on the shape of sickle upon deoxygenation. This results in multiple downstream effects including RBC adhesion, microvascular occlusion and chronic hemolysis. RBCs rely solely on anaerobic glycolysis to produce adenosine triphosphate (ATP), which is needed to maintain the cell's structure and function. Pyruvate kinase (PK) is a key enzyme involved in the last step of glycolysis. We have previously demonstrated a decrease in PK activity and stability as a novel pathophysiological feature of SCD. Currently there are several clinical trials ongoing investigating the efficacy of PK activation by small molecules such as mitapivat (NL8517, NCT04000165, NCT05031780), AG-946 (NCT04536792) and etavopivat (NCT04624659, NCT04987489). In this study we aim to investigate how PK properties correlate to sickle RBC properties in order to explore if impaired PK function is associated with specific features of the complex SCD pathophysiology. Methods: Homozygous HbS (HbSS) and HbS/ β 0 thalassemia patients were eligible to participate. Patients who received blood transfusion (&lt;3 months) were excluded. Dense RBCs (MCHC &gt;41 g/dL, Advia 120/2120 Siemens) and HbF and HbS levels (Tosoh G8) were measured. PK and hexokinase (HK) activity were measured on purified RBCs. PK thermostability (reflected by % residual PK activity) was measured on purified RBCs lysates after one hour of incubation (53°C). RBC adhesion to laminin (Biolamina) was measured using a microfluidic device (IBIDI µ-Slide I 0.4). RBC hydration (Ohyper), RBC deformability (EImax) and point of sickling (PoS) were assessed by osmotic and oxygen gradient ektacytometry using the Laser-Optical Rotational Red Cell Analyzer (Lorrca, RR Mechatronics). Oxygen affinity (P50) was measured with the Hemox-Analyzer (TCS). Statistical analysis was performed in Graphpad Prism (Pearson's correlation). Results: Fifty-seven patients with SCD (53 HbSS, 4 HbS/β 0 thalassemia) were included of which 17 were children (median age 14 years [range 6-17]) and 40 were adults (median age 36 years [range 18-58]). Baseline characteristics are depicted in Table 1. Figure 1 shows a heatmap with correlation coefficients of all laboratory parameters from Table 1 as measured in this cohort. When focusing on PK properties we found that patients with SCD and lower PK thermostability had significantly higher absolute reticulocyte counts (ARC, p&lt;0.0001), lower hemoglobin (p=0.012) and HbF (p=0.020) levels and increased RBC adhesion to laminin (p=0.007). Furthermore, PK thermostability was significantly correlated with EImax (p=0.017) and inversely correlated with PoS (p=0.011) and P50 (p=0.003), indicating that patients with less stable RBC PK had less deformable RBCs which sickled at a higher oxygen tension. RBC adhesion to laminin was significantly correlated with both ARC (p=0.0003) and dense RBCs (p=0.019). To explore whether our findings were a reflection of reticulocytosis we fractionated whole blood samples of HbSS patients according to cell density. We found that more RBCs from the most dense fraction adhered to laminin than from the less dense, reticulocyte enriched, fraction, even though RBCs from this less dense fraction had reduced PK-thermostability. Additionally, the most dense RBCs had the lowest PK activity, were less deformable and had a higher PoS (data not shown). Altogether these findings indicate that the reduced PK thermostability we found in our SCD cohort is associated with an overall functionally impaired RBC population with increased RBC adhesion and ARC. We found no correlation of markers of RBC dehydration (Ohyper and % dense RBCs) with PK thermostability which suggests that RBCs with reduced PK thermostability are not more dehydrated. Discussion/conclusion: This study shows for the first time a significant correlation between PK thermostability in sickle RBCs and RBC functions, such as adhesion, deformability and oxygen affinity. Our results suggest that enhancing the activity and stability of PK, with PK activators, is an attractive target in SCD that might improve other pathophysiological targets outside RBC metabolism. Future studies are needed to explore how activation of PK will affect these altered sickle RBC properties in vivo. Kidane:CSL Behring: Research Funding. Schols:Bayer: Research Funding. Cnossen:NWO, NWA, ZonMW, the Dutch Innovatiefonds Zorgverzekeraars, Stichting Haemophilia, Baxter/Baxalta/Shire/Takeda, Pfizer, Bayer Schering Pharma, CSL Behring, Sobi Biogen, Novo Nordisk, Novartis, Roche, and Nordic Pharma: Research Funding; Roche, Bayer and Novartis: Membership on an entity's Board of Directors or advisory committees. Nur:Amgen: Consultancy, Speakers Bureau; VERTEX: Consultancy, Speakers Bureau; Novartis: Consultancy, Research Funding, Speakers Bureau. Biemond:BMS: Research Funding; Sanquin: Research Funding; Novo Nordisk: Other: Advisory board; Novartis: Other: Advisory board, Research Funding; Celgene: Other: Advisory board; Global Blood Therapeutics/Pfizer: Other: Advisory board, Research Funding; CSL Behring: Other: Advisory board. Van Beers:Agios Pharmaceuticals, Inc.: Consultancy, Research Funding; Pfizer: Consultancy. Rijneveld:BMS: Honoraria; Servier: Honoraria. van Wijk:Agios Pharmaceuticals, Inc.: Consultancy, Research Funding; Pfizer, Inc.: Consultancy, Research Funding; RR Mechatronics: Research Funding; Axcella Therapeutics, Inc.: Research Funding. Rab:Agios Pharmaceuticals: Research Funding; Pfizer: Research Funding. [Display omitted]</description><identifier>ISSN: 0006-4971</identifier><identifier>EISSN: 1528-0020</identifier><identifier>DOI: 10.1182/blood-2023-180755</identifier><language>eng</language><publisher>Elsevier Inc</publisher><ispartof>Blood, 2023-11, Vol.142 (Supplement 1), p.561-561</ispartof><rights>2023 The American Society of Hematology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27906,27907</link.rule.ids></links><search><creatorcontrib>Traets, Marissa J.M.</creatorcontrib><creatorcontrib>van der Veen, Sigrid</creatorcontrib><creatorcontrib>Bos, Jennifer</creatorcontrib><creatorcontrib>van Pelt, Laura</creatorcontrib><creatorcontrib>Kidane, Aida</creatorcontrib><creatorcontrib>van Oirschot, Brigitte A.</creatorcontrib><creatorcontrib>van Solinge, Wouter W.</creatorcontrib><creatorcontrib>Schols, Saskia</creatorcontrib><creatorcontrib>Lauw, Mandy N.</creatorcontrib><creatorcontrib>Cnossen, Marjon H.</creatorcontrib><creatorcontrib>Nur, Erfan</creatorcontrib><creatorcontrib>Biemond, Bart J.</creatorcontrib><creatorcontrib>Van Beers, Eduard J.</creatorcontrib><creatorcontrib>Rijneveld, Anita W.</creatorcontrib><creatorcontrib>van Wijk, Richard</creatorcontrib><creatorcontrib>Rab, Minke A.E.</creatorcontrib><title>Pyruvate Kinase Thermostability Is Associated with Red Blood Cell Adhesion, Deformability and Oxygen Affinity in Patients with Sickle Cell Disease</title><title>Blood</title><description>Introduction: Sickle cell disease(SCD) is caused by a mutation in the beta globin gene that causes formation of abnormal hemoglobin S (HbS). Red blood cells (RBCs) from patients with SCD are less deformable and take on the shape of sickle upon deoxygenation. This results in multiple downstream effects including RBC adhesion, microvascular occlusion and chronic hemolysis. RBCs rely solely on anaerobic glycolysis to produce adenosine triphosphate (ATP), which is needed to maintain the cell's structure and function. Pyruvate kinase (PK) is a key enzyme involved in the last step of glycolysis. We have previously demonstrated a decrease in PK activity and stability as a novel pathophysiological feature of SCD. Currently there are several clinical trials ongoing investigating the efficacy of PK activation by small molecules such as mitapivat (NL8517, NCT04000165, NCT05031780), AG-946 (NCT04536792) and etavopivat (NCT04624659, NCT04987489). In this study we aim to investigate how PK properties correlate to sickle RBC properties in order to explore if impaired PK function is associated with specific features of the complex SCD pathophysiology. Methods: Homozygous HbS (HbSS) and HbS/ β 0 thalassemia patients were eligible to participate. Patients who received blood transfusion (&lt;3 months) were excluded. Dense RBCs (MCHC &gt;41 g/dL, Advia 120/2120 Siemens) and HbF and HbS levels (Tosoh G8) were measured. PK and hexokinase (HK) activity were measured on purified RBCs. PK thermostability (reflected by % residual PK activity) was measured on purified RBCs lysates after one hour of incubation (53°C). RBC adhesion to laminin (Biolamina) was measured using a microfluidic device (IBIDI µ-Slide I 0.4). RBC hydration (Ohyper), RBC deformability (EImax) and point of sickling (PoS) were assessed by osmotic and oxygen gradient ektacytometry using the Laser-Optical Rotational Red Cell Analyzer (Lorrca, RR Mechatronics). Oxygen affinity (P50) was measured with the Hemox-Analyzer (TCS). Statistical analysis was performed in Graphpad Prism (Pearson's correlation). Results: Fifty-seven patients with SCD (53 HbSS, 4 HbS/β 0 thalassemia) were included of which 17 were children (median age 14 years [range 6-17]) and 40 were adults (median age 36 years [range 18-58]). Baseline characteristics are depicted in Table 1. Figure 1 shows a heatmap with correlation coefficients of all laboratory parameters from Table 1 as measured in this cohort. When focusing on PK properties we found that patients with SCD and lower PK thermostability had significantly higher absolute reticulocyte counts (ARC, p&lt;0.0001), lower hemoglobin (p=0.012) and HbF (p=0.020) levels and increased RBC adhesion to laminin (p=0.007). Furthermore, PK thermostability was significantly correlated with EImax (p=0.017) and inversely correlated with PoS (p=0.011) and P50 (p=0.003), indicating that patients with less stable RBC PK had less deformable RBCs which sickled at a higher oxygen tension. RBC adhesion to laminin was significantly correlated with both ARC (p=0.0003) and dense RBCs (p=0.019). To explore whether our findings were a reflection of reticulocytosis we fractionated whole blood samples of HbSS patients according to cell density. We found that more RBCs from the most dense fraction adhered to laminin than from the less dense, reticulocyte enriched, fraction, even though RBCs from this less dense fraction had reduced PK-thermostability. Additionally, the most dense RBCs had the lowest PK activity, were less deformable and had a higher PoS (data not shown). Altogether these findings indicate that the reduced PK thermostability we found in our SCD cohort is associated with an overall functionally impaired RBC population with increased RBC adhesion and ARC. We found no correlation of markers of RBC dehydration (Ohyper and % dense RBCs) with PK thermostability which suggests that RBCs with reduced PK thermostability are not more dehydrated. Discussion/conclusion: This study shows for the first time a significant correlation between PK thermostability in sickle RBCs and RBC functions, such as adhesion, deformability and oxygen affinity. Our results suggest that enhancing the activity and stability of PK, with PK activators, is an attractive target in SCD that might improve other pathophysiological targets outside RBC metabolism. Future studies are needed to explore how activation of PK will affect these altered sickle RBC properties in vivo. Kidane:CSL Behring: Research Funding. Schols:Bayer: Research Funding. Cnossen:NWO, NWA, ZonMW, the Dutch Innovatiefonds Zorgverzekeraars, Stichting Haemophilia, Baxter/Baxalta/Shire/Takeda, Pfizer, Bayer Schering Pharma, CSL Behring, Sobi Biogen, Novo Nordisk, Novartis, Roche, and Nordic Pharma: Research Funding; Roche, Bayer and Novartis: Membership on an entity's Board of Directors or advisory committees. Nur:Amgen: Consultancy, Speakers Bureau; VERTEX: Consultancy, Speakers Bureau; Novartis: Consultancy, Research Funding, Speakers Bureau. Biemond:BMS: Research Funding; Sanquin: Research Funding; Novo Nordisk: Other: Advisory board; Novartis: Other: Advisory board, Research Funding; Celgene: Other: Advisory board; Global Blood Therapeutics/Pfizer: Other: Advisory board, Research Funding; CSL Behring: Other: Advisory board. Van Beers:Agios Pharmaceuticals, Inc.: Consultancy, Research Funding; Pfizer: Consultancy. Rijneveld:BMS: Honoraria; Servier: Honoraria. van Wijk:Agios Pharmaceuticals, Inc.: Consultancy, Research Funding; Pfizer, Inc.: Consultancy, Research Funding; RR Mechatronics: Research Funding; Axcella Therapeutics, Inc.: Research Funding. Rab:Agios Pharmaceuticals: Research Funding; Pfizer: Research Funding. [Display omitted]</description><issn>0006-4971</issn><issn>1528-0020</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kE1OwzAQhS0EEqVwAHY-AAE7seNUrELLT0WlVlDWlmNPqCGNkR0KuQYnJiGwZTWj0bw3bz6ETik5pzSLL4rKORPFJE4imhHB-R4aUR5nESEx2UcjQkgasYmgh-gohBdCKEtiPkJfq9a_71QD-N7WKgBeb8BvXWhUYSvbtHgecB6C07bbMfjDNhv80DVX_T08harCudlAsK4-wzMond_-KVVt8PKzfYYa52Vp635ma7xSjYW6CYPXo9WvFQxGMxugi3CMDkpVBTj5rWP0dHO9nt5Fi-XtfJovIk0TwSOVZExkimUCVKKLtOBEsMSYtCCgDStTZjKRAiexKtLYUG6EKOiEGgGs1MIkY0QHX-1dCB5K-ebtVvlWUiJ7qPIHquyhygFqp7kcNNAF21nwMujuGw3GetCNNM7-o_4GObuCAQ</recordid><startdate>20231102</startdate><enddate>20231102</enddate><creator>Traets, Marissa J.M.</creator><creator>van der Veen, Sigrid</creator><creator>Bos, Jennifer</creator><creator>van Pelt, Laura</creator><creator>Kidane, Aida</creator><creator>van Oirschot, Brigitte A.</creator><creator>van Solinge, Wouter W.</creator><creator>Schols, Saskia</creator><creator>Lauw, Mandy N.</creator><creator>Cnossen, Marjon H.</creator><creator>Nur, Erfan</creator><creator>Biemond, Bart J.</creator><creator>Van Beers, Eduard J.</creator><creator>Rijneveld, Anita W.</creator><creator>van Wijk, Richard</creator><creator>Rab, Minke A.E.</creator><general>Elsevier Inc</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20231102</creationdate><title>Pyruvate Kinase Thermostability Is Associated with Red Blood Cell Adhesion, Deformability and Oxygen Affinity in Patients with Sickle Cell Disease</title><author>Traets, Marissa J.M. ; van der Veen, Sigrid ; Bos, Jennifer ; van Pelt, Laura ; Kidane, Aida ; van Oirschot, Brigitte A. ; van Solinge, Wouter W. ; Schols, Saskia ; Lauw, Mandy N. ; Cnossen, Marjon H. ; Nur, Erfan ; Biemond, Bart J. ; Van Beers, Eduard J. ; Rijneveld, Anita W. ; van Wijk, Richard ; Rab, Minke A.E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1375-a38478a487ea3cb6b50743dd6b0ecd4f64d876e502ab62d15d77b191d7e4fc7d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Traets, Marissa J.M.</creatorcontrib><creatorcontrib>van der Veen, Sigrid</creatorcontrib><creatorcontrib>Bos, Jennifer</creatorcontrib><creatorcontrib>van Pelt, Laura</creatorcontrib><creatorcontrib>Kidane, Aida</creatorcontrib><creatorcontrib>van Oirschot, Brigitte A.</creatorcontrib><creatorcontrib>van Solinge, Wouter W.</creatorcontrib><creatorcontrib>Schols, Saskia</creatorcontrib><creatorcontrib>Lauw, Mandy N.</creatorcontrib><creatorcontrib>Cnossen, Marjon H.</creatorcontrib><creatorcontrib>Nur, Erfan</creatorcontrib><creatorcontrib>Biemond, Bart J.</creatorcontrib><creatorcontrib>Van Beers, Eduard J.</creatorcontrib><creatorcontrib>Rijneveld, Anita W.</creatorcontrib><creatorcontrib>van Wijk, Richard</creatorcontrib><creatorcontrib>Rab, Minke A.E.</creatorcontrib><collection>CrossRef</collection><jtitle>Blood</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Traets, Marissa J.M.</au><au>van der Veen, Sigrid</au><au>Bos, Jennifer</au><au>van Pelt, Laura</au><au>Kidane, Aida</au><au>van Oirschot, Brigitte A.</au><au>van Solinge, Wouter W.</au><au>Schols, Saskia</au><au>Lauw, Mandy N.</au><au>Cnossen, Marjon H.</au><au>Nur, Erfan</au><au>Biemond, Bart J.</au><au>Van Beers, Eduard J.</au><au>Rijneveld, Anita W.</au><au>van Wijk, Richard</au><au>Rab, Minke A.E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pyruvate Kinase Thermostability Is Associated with Red Blood Cell Adhesion, Deformability and Oxygen Affinity in Patients with Sickle Cell Disease</atitle><jtitle>Blood</jtitle><date>2023-11-02</date><risdate>2023</risdate><volume>142</volume><issue>Supplement 1</issue><spage>561</spage><epage>561</epage><pages>561-561</pages><issn>0006-4971</issn><eissn>1528-0020</eissn><abstract>Introduction: Sickle cell disease(SCD) is caused by a mutation in the beta globin gene that causes formation of abnormal hemoglobin S (HbS). Red blood cells (RBCs) from patients with SCD are less deformable and take on the shape of sickle upon deoxygenation. This results in multiple downstream effects including RBC adhesion, microvascular occlusion and chronic hemolysis. RBCs rely solely on anaerobic glycolysis to produce adenosine triphosphate (ATP), which is needed to maintain the cell's structure and function. Pyruvate kinase (PK) is a key enzyme involved in the last step of glycolysis. We have previously demonstrated a decrease in PK activity and stability as a novel pathophysiological feature of SCD. Currently there are several clinical trials ongoing investigating the efficacy of PK activation by small molecules such as mitapivat (NL8517, NCT04000165, NCT05031780), AG-946 (NCT04536792) and etavopivat (NCT04624659, NCT04987489). In this study we aim to investigate how PK properties correlate to sickle RBC properties in order to explore if impaired PK function is associated with specific features of the complex SCD pathophysiology. Methods: Homozygous HbS (HbSS) and HbS/ β 0 thalassemia patients were eligible to participate. Patients who received blood transfusion (&lt;3 months) were excluded. Dense RBCs (MCHC &gt;41 g/dL, Advia 120/2120 Siemens) and HbF and HbS levels (Tosoh G8) were measured. PK and hexokinase (HK) activity were measured on purified RBCs. PK thermostability (reflected by % residual PK activity) was measured on purified RBCs lysates after one hour of incubation (53°C). RBC adhesion to laminin (Biolamina) was measured using a microfluidic device (IBIDI µ-Slide I 0.4). RBC hydration (Ohyper), RBC deformability (EImax) and point of sickling (PoS) were assessed by osmotic and oxygen gradient ektacytometry using the Laser-Optical Rotational Red Cell Analyzer (Lorrca, RR Mechatronics). Oxygen affinity (P50) was measured with the Hemox-Analyzer (TCS). Statistical analysis was performed in Graphpad Prism (Pearson's correlation). Results: Fifty-seven patients with SCD (53 HbSS, 4 HbS/β 0 thalassemia) were included of which 17 were children (median age 14 years [range 6-17]) and 40 were adults (median age 36 years [range 18-58]). Baseline characteristics are depicted in Table 1. Figure 1 shows a heatmap with correlation coefficients of all laboratory parameters from Table 1 as measured in this cohort. When focusing on PK properties we found that patients with SCD and lower PK thermostability had significantly higher absolute reticulocyte counts (ARC, p&lt;0.0001), lower hemoglobin (p=0.012) and HbF (p=0.020) levels and increased RBC adhesion to laminin (p=0.007). Furthermore, PK thermostability was significantly correlated with EImax (p=0.017) and inversely correlated with PoS (p=0.011) and P50 (p=0.003), indicating that patients with less stable RBC PK had less deformable RBCs which sickled at a higher oxygen tension. RBC adhesion to laminin was significantly correlated with both ARC (p=0.0003) and dense RBCs (p=0.019). To explore whether our findings were a reflection of reticulocytosis we fractionated whole blood samples of HbSS patients according to cell density. We found that more RBCs from the most dense fraction adhered to laminin than from the less dense, reticulocyte enriched, fraction, even though RBCs from this less dense fraction had reduced PK-thermostability. Additionally, the most dense RBCs had the lowest PK activity, were less deformable and had a higher PoS (data not shown). Altogether these findings indicate that the reduced PK thermostability we found in our SCD cohort is associated with an overall functionally impaired RBC population with increased RBC adhesion and ARC. We found no correlation of markers of RBC dehydration (Ohyper and % dense RBCs) with PK thermostability which suggests that RBCs with reduced PK thermostability are not more dehydrated. Discussion/conclusion: This study shows for the first time a significant correlation between PK thermostability in sickle RBCs and RBC functions, such as adhesion, deformability and oxygen affinity. Our results suggest that enhancing the activity and stability of PK, with PK activators, is an attractive target in SCD that might improve other pathophysiological targets outside RBC metabolism. Future studies are needed to explore how activation of PK will affect these altered sickle RBC properties in vivo. Kidane:CSL Behring: Research Funding. Schols:Bayer: Research Funding. Cnossen:NWO, NWA, ZonMW, the Dutch Innovatiefonds Zorgverzekeraars, Stichting Haemophilia, Baxter/Baxalta/Shire/Takeda, Pfizer, Bayer Schering Pharma, CSL Behring, Sobi Biogen, Novo Nordisk, Novartis, Roche, and Nordic Pharma: Research Funding; Roche, Bayer and Novartis: Membership on an entity's Board of Directors or advisory committees. Nur:Amgen: Consultancy, Speakers Bureau; VERTEX: Consultancy, Speakers Bureau; Novartis: Consultancy, Research Funding, Speakers Bureau. Biemond:BMS: Research Funding; Sanquin: Research Funding; Novo Nordisk: Other: Advisory board; Novartis: Other: Advisory board, Research Funding; Celgene: Other: Advisory board; Global Blood Therapeutics/Pfizer: Other: Advisory board, Research Funding; CSL Behring: Other: Advisory board. Van Beers:Agios Pharmaceuticals, Inc.: Consultancy, Research Funding; Pfizer: Consultancy. Rijneveld:BMS: Honoraria; Servier: Honoraria. van Wijk:Agios Pharmaceuticals, Inc.: Consultancy, Research Funding; Pfizer, Inc.: Consultancy, Research Funding; RR Mechatronics: Research Funding; Axcella Therapeutics, Inc.: Research Funding. Rab:Agios Pharmaceuticals: Research Funding; Pfizer: Research Funding. [Display omitted]</abstract><pub>Elsevier Inc</pub><doi>10.1182/blood-2023-180755</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0006-4971
ispartof Blood, 2023-11, Vol.142 (Supplement 1), p.561-561
issn 0006-4971
1528-0020
language eng
recordid cdi_crossref_primary_10_1182_blood_2023_180755
source EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
title Pyruvate Kinase Thermostability Is Associated with Red Blood Cell Adhesion, Deformability and Oxygen Affinity in Patients with Sickle Cell Disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T10%3A52%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pyruvate%20Kinase%20Thermostability%20Is%20Associated%20with%20Red%20Blood%20Cell%20Adhesion,%20Deformability%20and%20Oxygen%20Affinity%20in%20Patients%20with%20Sickle%20Cell%20Disease&rft.jtitle=Blood&rft.au=Traets,%20Marissa%20J.M.&rft.date=2023-11-02&rft.volume=142&rft.issue=Supplement%201&rft.spage=561&rft.epage=561&rft.pages=561-561&rft.issn=0006-4971&rft.eissn=1528-0020&rft_id=info:doi/10.1182/blood-2023-180755&rft_dat=%3Celsevier_cross%3ES0006497123051650%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S0006497123051650&rfr_iscdi=true